Anthropic hopes Powerful AI will “match or exceed the cognitive capabilities of top human experts across scientific disciplines”.

Xtandi's label as the cancer treatment paradigm shifts towards the use of mutation-specific targeted therapies.

Reaction from the life sciences industry to the Autumn Budget was mixed, with the government opting for a more macro focus on business scaling.

Enthorin has signed an option-to-license deal with Rumi to advance ENT-7340 for FXS, as well as other intellectual and developmental disabilities.

Formation Bio has launched the Formation Bio Drug Development Accelerator Fund to broaden the company's clinical-stage medicines portfolio.